Table 3.

Patient Characteristics of Trial Participants

Reference phase 3 trials in GBM (n = 10)
Trial Participants		No. of Trials	References
Median age of randomized cohorts, years (range)	56.5 (54.0–59.0)	9a	8–16
Male:female ratio (range)	1.5:1 (1.2–2.1:1)	10	7–16
ECOG, median	0-1b	10	7–16
Surgical resection, median % (range)	97 (87–100)	10	7–16
Median survival, months (range)	16.8 (16.0–20.0)	7c	7–9,11–14
2-year survival, median % (range)	33.9 (30.1–40.0)	5d	7,9,11–13

Characteristics of trial participants extracted from the phase 3 trials used as reference trials.

ECOG, Eastern Cooperative Oncology Group.

^aOne study did not report median age of the patients.

^bPerformance status is reported over an interval as it was converted from KPS in 8 studies that could not discern a true median value.

^cThree studies were excluded from survival calculations as 2 recruited MGMT-methylated tumors and one did not have an adequate control group.

^dOnly 5 studies specifically reported 2-year survival characteristics.